Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration

Clinical Therapeutics

Volumn 30, Issue 12, 2008, Pages 2436-2451

  Hernandez Pastor, Luis Javier ^a   Ortega, Ana ^a   Garcia Layana, Alfredo ^a   Giraldez, Joaquin ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

age related macular degeneration; cost utility; cost effectiveness; photodynamic therapy; ranibizumab

Indexed keywords

RANIBIZUMAB; VERTEPORFIN;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; HOSPITAL COST; HUMAN; LIFE EXPECTANCY; MONOTHERAPY; PHOTODYNAMIC THERAPY; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RETINA MACULA AGE RELATED DEGENERATION; SENSITIVITY ANALYSIS; SPAIN; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; CHOROIDAL NEOVASCULARIZATION; COST-BENEFIT ANALYSIS; HUMANS; INJECTIONS; INSURANCE, HEALTH, REIMBURSEMENT; MACULAR DEGENERATION; MARKOV CHAINS; MIDDLE AGED; PHOTOCHEMOTHERAPY; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; SPAIN; VISUAL ACUITY;

EID: 58349119393     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.12.025     Document Type: Article

References (58)

1. Resnikoff S., Pascolini D., Etya'ale D., et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 82 (2004) 844-851
2. Jager R.D., Mieler W.F., and Miller J.W. Age-related macular degeneration. N Engl J Med. 358 (2008) 2606-2617
3. de Jong P.T. Age-related macular degeneration. N Engl J Med. 355 (2006) 1474-1485
4. Chakravarthy U., Soubrane G., Bandello F., et al. Evolving European guidance on the medical management of neovascular age related macular degeneration. Br J Ophthalmol. 90 (2006) 1188-1196
5. Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: Update. Retina. 25 (2005) 119-134
6. Rosenfeld P.J., Brown D.M., Heier J.S., et al., MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 355 (2006) 1419-1431
7. Brown D.M., Kaiser P.K., Michels M., et al., ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 355 (2006) 1432-1444
8. Heier J.S., Boyer D.S., Ciulla T.A., et al., FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: Year 1 results of the FOCUS Study. [published correction appears in Arch Ophthalmol. 2007;125:138]. Arch Ophthalmol. 124 (2006) 1532-1542
9. Regillo C.D., Brown D.M., Abraham P., et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 145 (2008) 239-248
10. Falkenstein I.A., Cochran D.E., Azen S.P., et al. Comparison of visual acuity in macular degeneration patients measured with Snellen and early treatment diabetic retinopathy study charts. Ophthalmology. 115 (2008) 319-323
11. Arias L., Armadá F., Donate J., et al. Delay in treating agerelated macular degeneration in Spain is associated with progressive vision loss. Eye (2008 Jan 18) [Epub ahead of print]
12. Kourlas H., and Abrams P. Ranibizumab for the treatment of neovascular age-related macular degeneration: A review. Clin Ther. 29 (2007) 1850-1861
13. Blick S.K., Keating G.M., and Wagstaff A.J. Ranibizumab. Drugs. 67 (2007) 1199-1206 discussion 1207-1209
14. Wormald R., Evans J., Smeeth L., and Henshaw K. Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev. (2007) CD002030
15. Meads C., Salas C., Roberts T., et al. Clinical effectiveness and cost-utility of photodynamic therapy for wet agerelated macular degeneration: A systematic review and economic evaluation. Health Technol Assess. 7 (2003) v-vi
16. Meads C., Salas C., Roberts T., et al. Clinical effectiveness and cost-utility of photodynamic therapy for wet agerelated macular degeneration: A systematic review and economic evaluation. Health Technol Assess. 7 (2003) 1-98
17. Tablas de supervivencia de la población española: Instituto Nacional de Estadística [National Statistics Institute].
18. (September 23, 2008). http://www.ine.es/jaxi/tabla.do?path=/t20/p319a/1992-2005/l0/&file=0 1001.px&type=pcaxis Accessed
19. Heier J.S. Ranibizumab: Two-year ANCHOR Study. Presented at: American Academy of Ophthalmology 2007 annual meeting, New Orleans, Louisiana, November 10-13 (2007)
20. Drummond M., Sculpher M., Torrance G., et al. Economic evaluation using decision analytic modelling. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. (2005), Oxford University Press, Oxford, NY 277-314
21. Bressler N.M., and Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol. 119 (2001) 198-207
22. Kaiser P.K., and Treatment of Age- Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-Year results of two randomized clinical trials with an open-label extension: TAP report no. 8. Graefes Arch Clin Exp Ophthalmol 244 (2006) 1132-1142
23. Brown G.C. Vision and quality-of-life. Trans Am Ophthalmol Soc. 97 (1999) 473-511
24. Brown G.C. Vision and quality-of-life. Am J Ophthalmol. 129 (2000) 833
25. Brown G.C., Sharma S., Brown M.M., and Kistler J. Utility values and age-related macular degeneration. Arch Ophthalmol. 118 (2000) 47-51
26. Brown M.M., Brown G.C., Sharma S., et al. Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Arch Ophthalmol. 120 (2002) 481-484
27. Sharma S., Brown G.C., Brown M.M., et al. Validity of the time trade-off and standard gamble methods of utility assessment in retinal patients. Br J Ophthalmol. 86 (2002) 493-496
28. Drummond M., Sculpher M., Torrance G., et al. Cost analysis. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. (2005), Oxford University Press, Oxford, NY 55-95
29. Briggs A.H. Handling uncertainty in cost-effectiveness models. Pharmaco-Economics. 17 (2000) 479-500
30. Briggs A.H. Handling uncertainty in economic evaluation and presenting the results. In: Drummond M., and McGuire A. (Eds). Economic Evaluation in Health Care: Merging Theory with Practice (2001), Oxford University Press, Oxford, NY 172-214
31. Fung A.E., Lalwani G.A., Rosenfeld P.J., et al. An optical coherence tomographyguided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 143 (2007) 566-583
32. Rosenfeld P.J., and PrONTO study group. Ranibizumab: The PrONTO study. Presented at: American Academy of Ophthalmology 2007 annual meeting, New Orleans, Louisiana, November 10-13 (2007)
33. Meyer C.H., Eter N., and Holz F.G. Ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Interim results from the SUSTAIN Trial. Presented at: Association for Research in Vision and Ophthalmology 2008 annual meeting, Fort Lauderdale, Florida, April 27-May 1 (2008)
34. Brown D.M., and Regillo C.D. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: Applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol. 144 (2007) 627-637
35. Dadgostar H., and Waheed N. The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration. Eye 22 (2008) 761-767
36. Drummond M., Sculpher M., Torrance G., et al. Basic types of economic evaluation. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. (2005), Oxford University Press, Oxford, NY 7-26
37. Sharma S., Brown G.C., Brown M.M., et al. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 108 (2001) 2051-2059
38. Hopley C., Salkeld G., and Mitchell P. Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration. Br J Ophthalmol. 88 (2004) 982-987
39. Smith D.H., Fenn P., and Drummond M. Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: The UK case. Br J Ophthalmol. 88 (2004) 1107-1112
40. Brown G.C., Brown M.M., Campanella J., and Beauchamp G.R. The costutility of photodynamic therapy in eyes with neovascular macular degeneration-a value-based reappraisal with 5-year data. Am J Ophthalmol. 140 (2005) 679-687
41. Bansback N., Davis S., and Brazier J. Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration. Eye. 21 (2007) 1455-1463
42. Muslera E., and Natal C. Cost-effectiveness of photodynamic therapy in agerelated macular degeneration [in Spanish]. Arch Soc Esp Oftalmol. 81 (2006) 199-204
43. Greiner R.A. Cost of care for patients with age-related macular degeneration in Switzerland and costeffectiveness of treatment with verteporfin therapy. Semin Ophthalmol. 16 (2001) 218-222
44. Bansback N., Czoski-Murray C., Carlton J., et al. Determinants of health related quality of life and health state utility in patients with age related macular degeneration: The association of contrast sensitivity and visual acuity. Qual Life Res. 16 (2007) 533-543
45. Brown A, Hodge W, Kymes S, et al, for the Canadian Agency for Drugs and Technologies in Health (CADTH). Management of neovascular age-related macular degeneration: Systematic drug class review and economic evaluation.
46. (June 4, 2008). http://www.cadth.ca/index.php/en/hta/reports-publications/search/publica tion/814 Accessed
47. Brown G.C., Brown M.M., Brown H.C., et al. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration. Ophthalmology. 114 (2007) 1170-1178
48. Colquitt J.L., Jones J., Tan S.C., et al. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: A systematic review and economic evaluation. Health Technol Assess. 12 (2008) iii-iv ix-201
49. Grosse S. Assessing cost-effectiveness in healthcare: History of the $50,000 per QALY threshold. Expert Review of PharmacoEconomics & Outcomes Research. 2008;8:165-178.
50. (December 1, 2008). http://www.expert-reviews.com/page/indexing#inderp Accessed
51. McCabe C., Claxton K., and Culyer A.J. The NICE cost-effectiveness threshold: What it is and what that means. PharmacoEconomics. 26 (2008) 733-744
52. Soto A.J. New drugs in Spain- when are they to be considered cost-effective alternatives and profitable investments for the National Health System [in Spanish]?. Farm Hosp. 28 (2004) 299-304
53. Birch S., and Gafni A. Information created to evade reality (ICER): Things we should not look to for answers. PharmacoEconomics. 24 (2006) 1121-1131
54. Birch S., and Gafni A. The biggest bang for the buck or bigger bucks for the bang: The fallacy of the costeffectiveness threshold. J Health Serv Res Policy. 11 (2006) 46-51
55. National Eye Institute. Comparison of AMD Treatments Trials (CATT): Lucentis - Avastin Trial. A multicenter clinical trial to compare the relative safety and effectiveness of two drugs currently used to treat advanced age-related macular degeneration (AMD).
56. (September 23, 2008). http://www.nei.nih.gov/CATT Accessed
57. Fine S.L., Berger J.W., Maguire M.G., and Ho A.C. Age-related macular degeneration. N Engl J Med. 342 (2000) 483-492
58. Soubrane G., Cruess A., Lotery A., et al. Burden and health care resource utilization in neovascular age-related macular degeneration: Findings of a multicountry study. Arch Ophthalmol. 125 (2007) 1249-1254